Last reviewed · How we verify
NCT06012565
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
Phase 2 trial testing KAND567 in Covid19 in 35 participants. Terminated before completion.
7 August 2021
Quick facts
| Lead sponsor | Novakand Pharma AB |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 11 October 2020 |
| Primary completion | 7 August 2021 |
| Estimated completion | 7 August 2021 |
| Sites | 4 locations across Denmark, Sweden |
Drugs / interventions tested
- KAND567 — full drug profile →
- Microcrystalline cellulose — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Novakand Pharma AB — full company profile →
Who can join
Adults 18 to 85, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment. The target was to include forty (40) subjects with diagnosed COVID-19 for participation in the study. If at screening all criteria for study participation were fulfilled and informed consent signed, the subject was enrolled and randomized into one of the two arms. After randomization, the subjects were to receive KAND567 or placebo treatment for 7 days. After the treatment period the subjects returned to ordinary clinical follow-up, but a study follow-up visit was to be planned for Day 21 and 90.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06012565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of KAND567
Trials testing the same drug.
- NCT06087289 — A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial O · Phase 1, PHASE2 · completed
- NCT06030375 — Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567 · Phase 1 · completed
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Novakand Pharma AB trials
Trials by the same sponsor.
- NCT06063343 — Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers A · Phase 1 · completed
- NCT06087289 — A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial O · Phase 1, PHASE2 · completed
- NCT06030375 — Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06012565 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novakand Pharma AB
- Last refreshed: 25 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06012565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing